Literature DB >> 16352555

Characterization of the vaccinia virus A35R protein and its role in virulence.

Rachel L Roper1.   

Abstract

The vaccinia virus A35R gene is highly conserved among poxviruses and encodes a previously uncharacterized hydrophobic acidic protein. Western blotting with anti-A35R peptide antibodies indicated that the protein is expressed early in infection and resolved as a single sharp band of approximately 23 kDa, slightly higher than the 20 kDa predicted from its sequence. The protein band appeared to be the same molecular weight on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, whether expressed in an in vitro transcription/translation system without microsomes or expressed in infected cells, suggesting that it was not glycosylated. A mutant virus with the A35R gene deleted (vA35Delta) formed wild-type-sized plaques on all cell lines tested (human, monkey, mouse, and rabbit); thus, A35R is not required for replication and does not appear to be a host range gene. Although the A35R protein is hydrophobic, it is unlikely to be an integral membrane protein, as it partitioned to the aqueous phase during TX-114 partitioning. The protein could not be detected in virus-infected cell supernatants. A35R localized intracellularly to the virus factories, where the first stages of morphogenesis occur. The vA35Delta mutant formed near-normal levels of the various morphogenic stages of infectious virus particles and supported normal acid-induced fusion of virus-infected cells. Despite normal growth and morphogenesis in vitro, the vA35Delta mutant virus was attenuated in intranasal challenge of mice compared to wild-type and A35R rescue virus. Thus, the intracellular A35R protein plays a role in virulence. The A35R has little homology to any protein outside of poxviruses, suggesting a novel virulence mechanism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16352555      PMCID: PMC1317533          DOI: 10.1128/JVI.80.1.306-313.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

Review 1.  Immunology 101 at poxvirus U: immune evasion genes.

Authors:  B Moss; J L Shisler
Journal:  Semin Immunol       Date:  2001-02       Impact factor: 11.130

2.  Immunomodulatory proteins of myxoma virus.

Authors:  J W Barrett; J X Cao; S Hota-Mitchell; G McFadden
Journal:  Semin Immunol       Date:  2001-02       Impact factor: 11.130

Review 3.  Immunology 102 at poxvirus U: avoiding apoptosis.

Authors:  J L Shisler; B Moss
Journal:  Semin Immunol       Date:  2001-02       Impact factor: 11.130

4.  Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.

Authors:  W H Zhang; D Wilcock; G L Smith
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Alastrim smallpox variola minor virus genome DNA sequences.

Authors:  S N Shchelkunov; A V Totmenin; V N Loparev; P F Safronov; V V Gutorov; V E Chizhikov; J C Knight; J M Parsons; R F Massung; J J Esposito
Journal:  Virology       Date:  2000-01-20       Impact factor: 3.616

Review 6.  Interferon-inducible chemokines and immunity to poxvirus infections.

Authors:  S Mahalingam; P S Foster; M Lobigs; J M Farber; G Karupiah
Journal:  Immunol Rev       Date:  2000-10       Impact factor: 12.988

7.  An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine.

Authors:  C R Damaso; J J Esposito; R C Condit; N Moussatché
Journal:  Virology       Date:  2000-11-25       Impact factor: 3.616

8.  The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence.

Authors:  M Engelstad; G L Smith
Journal:  Virology       Date:  1993-06       Impact factor: 3.616

9.  Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997.

Authors:  Y J Hutin; R J Williams; P Malfait; R Pebody; V N Loparev; S L Ropp; M Rodriguez; J C Knight; F K Tshioko; A S Khan; M V Szczeniowski; J J Esposito
Journal:  Emerg Infect Dis       Date:  2001 May-Jun       Impact factor: 6.883

10.  Vaccinia virus utilizes microtubules for movement to the cell surface.

Authors:  M Hollinshead; G Rodger; H Van Eijl; M Law; R Hollinshead; D J Vaux; G L Smith
Journal:  J Cell Biol       Date:  2001-07-23       Impact factor: 10.539

View more
  18 in total

1.  The poxvirus A35 protein is an immunoregulator.

Authors:  Kristina E Rehm; Gwendolyn J B Jones; Alice A Tripp; Mark W Metcalf; Rachel L Roper
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

2.  Ectromelia virus accumulates less double-stranded RNA compared to vaccinia virus in BS-C-1 cells.

Authors:  Tiffany R Frey; Michael H Lehmann; Colton M Ryan; Marie C Pizzorno; Gerd Sutter; Adam R Hersperger
Journal:  Virology       Date:  2017-09       Impact factor: 3.616

3.  Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.

Authors:  Kristina E Rehm; Rachel L Roper
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

4.  Antigen presentation assays to investigate uncharacterized immunoregulatory genes.

Authors:  Rachel L Roper
Journal:  Methods Mol Biol       Date:  2012

5.  Experimental Evolution Identifies Vaccinia Virus Mutations in A24R and A35R That Antagonize the Protein Kinase R Pathway and Accompany Collapse of an Extragenic Gene Amplification.

Authors:  Greg Brennan; Jacob O Kitzman; Jay Shendure; Adam P Geballe
Journal:  J Virol       Date:  2015-07-22       Impact factor: 5.103

Review 6.  A guide to viral inclusions, membrane rearrangements, factories, and viroplasm produced during virus replication.

Authors:  Christopher Netherton; Katy Moffat; Elizabeth Brooks; Thomas Wileman
Journal:  Adv Virus Res       Date:  2007       Impact factor: 9.937

7.  Vaccinia virus A35R inhibits MHC class II antigen presentation.

Authors:  Kristina E Rehm; Ramsey F Connor; Gwendolyn J B Jones; Kenneth Yimbu; Rachel L Roper
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

8.  Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II.

Authors:  Kristina E Rehm; Ramsey F Connor; Gwendolyn J B Jones; Kenneth Yimbu; Mark D Mannie; Rachel L Roper
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

9.  Attenuation of vaccinia Tian Tan strain by removal of viral TC7L-TK2L and TA35R genes.

Authors:  Shifu Kan; Yuhang Wang; Lili Sun; Peng Jia; Yanxin Qi; Jiaqiang Su; Lei Liu; Guohua Yang; Liming Liu; Zhuoyue Wang; Jinhui Wang; Guangchen Liu; Ningyi Jin; Xiao Li; Zhuang Ding
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

10.  Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).

Authors:  Matthew G Cottingham; Rikke F Andersen; Alexandra J Spencer; Saroj Saurya; Julie Furze; Adrian V S Hill; Sarah C Gilbert
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.